RxDoctor Payments Data

Timothy Petrosky, PA

Physician Assistant · Novi, MINPI 1609844208

Payments from drug & device makers

$7,568in general payments, 2019–2025

Across 396 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • AbbVie$1K
  • Collegium Pharmaceutical, Inc.$734
  • Nalu Medical, Inc.$442
  • Scilex Pharmaceuticals Inc.$428
  • IBSA Pharma Inc.$391
  • plus $3K from 29 others

What the payments were for

  • Food & beverage$7,568100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,568 in reported general payments places this provider in the 95th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$48,201
Medicare patients
153
Services billed
1,039

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine97$28,361
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl156$22,137
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen927$15,081
LinzessLinaclotide22$12,996
Aimovig AutoinjectorErenumab-Aooe12$9,728
Gabapentin493$6,760
BelbucaBuprenorphine Hcl12$5,456
OxycontinOxycodone Hcl14$5,039
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen316$4,991
Tramadol Hcl ErTramadol Hcl60$2,934
Morphine Sulfate ErMorphine Sulfate127$2,440
Oxycodone Hcl147$1,902
Baclofen98$1,579
Morphine Sulfate73$1,547
Pregabalin131$1,471

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,481$12,99622 claims
Collegium Pharmaceutical, Inc.Belbuca$734$5,45612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Novi

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →